Goldman Sachs
PCRX icon

Goldman Sachs’s Pacira BioSciences PCRX Stock Holding History

Goldman Sachs’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-25,000
Closed -$1.52M – 6442
2021
Q2 		$1.52M Hold
25,000
– – ﹤0.01% 4442
2021
Q1 		$1.75M Buy
+25,000
New +$1.79M ﹤0.01% 4119
2018
Q1 		– Sell
-3,700
Closed -$169K – 6265
2017
Q4 		$169K Buy
3,700
+900
+32% +$35.7K ﹤0.01% 5506
2017
Q3 		$105K Sell
2,800
-27,100
-91% -$1.09M ﹤0.01% 6045
2017
Q2 		$1.43M Sell
29,900
-15,800
-35% -$733K ﹤0.01% 4131
2017
Q1 		$2.08M Buy
45,700
+35,700
+357% +$1.54M ﹤0.01% 3702
2016
Q4 		$323K Sell
10,000
-2,200
-18% -$73.4K ﹤0.01% 5429
2016
Q3 		$417K Sell
12,200
-24,800
-67% -$972K ﹤0.01% 5204
2016
Q2 		$1.25M Sell
37,000
-11,300
-23% -$555K ﹤0.01% 4008
2016
Q1 		$2.56M Sell
48,300
-9,100
-16% -$532K ﹤0.01% 3260
2015
Q4 		$4.41M Buy
57,400
+50,600
+744% +$2.87M ﹤0.01% 2942
2015
Q3 		$279K Sell
6,800
-2,600
-28% -$159K ﹤0.01% 5684
2015
Q2 		$665K Hold
9,400
– – ﹤0.01% 4896
2015
Q1 		$835K Buy
9,400
+2,800
+42% +$284K ﹤0.01% 4642
2014
Q4 		$585K Sell
6,600
-13,000
-66% -$1.23M ﹤0.01% 5138
2014
Q3 		$1.9M Buy
19,600
+15,300
+356% +$1.49M ﹤0.01% 3985
2014
Q2 		$395K Buy
+4,300
New +$327K ﹤0.01% 5525
2013
Q4 		– Sell
-60,000
Closed -$2.88M – 6763
2013
Q3 		$2.88M Buy
60,000
+10,000
+20% +$364K ﹤0.01% 3537
2013
Q2 		$1.45M Buy
+50,000
New +$1.45M ﹤0.01% 4040

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs's PCRX Position: Q2 2026 in Review

Goldman Sachs reduced its Pacira BioSciences (PCRX) stake by 2.7% in Q2 2026, selling an estimated $1.01M and leaving 1,527,129 shares worth $38.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2029.

Goldman Sachs first reported a position in PCRX in Q2 2013 and has held it in 53 quarters since. The position peaked at $59M in Q2 2015. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Goldman Sachs held 1,527,129 shares of Pacira BioSciences worth $38.7M as of Q2 2026.
  • Goldman Sachs sold 42,787 Pacira BioSciences shares in Q2 2026, an estimated $1.01M.
  • Pacira BioSciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2029 holding.
  • Goldman Sachs first reported a position in Pacira BioSciences in Q2 2013 and has held it in 53 quarters since.
  • Goldman Sachs's Pacira BioSciences position peaked at $59M in Q2 2015.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.